X4 Pharmaceuticals, Inc. (XFOR): Price and Financial Metrics


X4 Pharmaceuticals, Inc. (XFOR): $1.23

-0.07 (-5.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XFOR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XFOR Stock Price Chart Interactive Chart >

Price chart for XFOR

XFOR Price/Volume Stats

Current price $1.23 52-week high $9.90
Prev. close $1.30 52-week low $1.00
Day low $1.17 Volume 395,014
Day high $1.40 Avg. volume 339,510
50-day MA $1.50 Dividend yield N/A
200-day MA $3.15 Market Cap 37.91M

X4 Pharmaceuticals, Inc. (XFOR) Company Bio


X4 Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company specializes in developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases including primary immunodeficiencies and cancer. X4's oral small molecule drug candidates antagonize the CXCR4 pathway which plays a central role in immune surveillance.


XFOR Latest News Stream


Event/Time News Detail
Loading, please wait...

XFOR Latest Social Stream


Loading social stream, please wait...

View Full XFOR Social Stream

Latest XFOR News From Around the Web

Below are the latest news stories about X4 Pharmaceuticals Inc that investors may wish to consider to help them evaluate XFOR as an investment opportunity.

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at B. Riley Securities Oncology Investor Conference on Friday, January 28, 2022. Details are as follows:Conference: B. Riley Securities Oncology Investor Conference Format: Fireside Chat Date: Friday,

Yahoo | January 19, 2022

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that, on December 31, 2021, the Compensation Committee of X4s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the 2019 Inducement Plan). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 37,650 shares of X4s common stock. These stock awards were granted as an inducement material to the new employees enterin...

GlobeNewswire | January 5, 2022

X4 Pharmaceuticals Inc. (NASDAQ: XFOR) Drops -351.48% From Highs, Now What?

During the last session, X4 Pharmaceuticals Inc. (NASDAQ:XFOR)’s traded shares were 1.29 million, with the beta value of the company hitting 0.43. At the end of the trading day, the stock’s price was $2.37, reflecting an intraday gain of 17.33% or $0.35. The 52-week high for the XFOR share is $10.70, that puts it down … X4 Pharmaceuticals Inc. (NASDAQ: XFOR) Drops -351.48% From Highs, Now What? Read More »

Marketing Sentinel | December 17, 2021

X4 Pharmaceuticals (XFOR) Gets a Buy Rating from B.Riley Financial

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of $10.00. The company's shares closed last Wednesday at $1.95, close to its 52-week low of $1.88. According to TipRanks.com, Mamtani is a 1-star analyst with an average return of -0.3% and a 36.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for X4 Pharmaceuticals with a $13.00 average price target, a 587.8% upside from current levels. In a report released yesterday, H.C.

Christine Brown on TipRanks | December 15, 2021

Data - HC Wainwright Lowers X4 Pharmaceuticals Price Target to $11.00

X4 Pharmaceuticals had its price target cut by HC Wainwright from $21.00 to $11.00 in a research note published on Tuesday, The Fly reports. They currently have a buy rating on

Business Mag | December 15, 2021

Read More 'XFOR' Stories Here

XFOR Price Returns

1-mo -5.38%
3-mo -16.89%
6-mo N/A
1-year -85.36%
3-year -92.84%
5-year N/A
YTD -46.29%
2021 -64.39%
2020 -39.91%
2019 -23.13%
2018 -81.82%
2017 N/A

Continue Researching XFOR

Want to see what other sources are saying about X4 Pharmaceuticals Inc's financials and stock price? Try the links below:

X4 Pharmaceuticals Inc (XFOR) Stock Price | Nasdaq
X4 Pharmaceuticals Inc (XFOR) Stock Quote, History and News - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9898 seconds.